Boosting COVID protection during long-term immune suppression
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study looks at how well a COVID-19 booster works in adults who need long-term medicines that lower immune response. It aims to see whether immunosuppressed people benefit from booster vaccination safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult age 18 or older
- You’ve had at least 2 COVID-19 vaccine shots, and your most recent dose was over 3 months ago
- You’re planning immune-suppressing treatment expected to continue for at least 1 year
- In the past 5 years, you have not taken cyclophosphamide, alemtuzumab, or rituximab
- You can freely sign a written consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.
This study tests the best timing for a COVID-19 booster and flu shot in people with weakened immune systems, such as organ transplant recipients, people living with HIV, or those with certain autoimmune conditions. It aims to help patients get better protection from both vaccines.
This trial tests an updated COVID-19 booster vaccine designed to improve protection for people who are older or have health conditions that increase their risk of severe COVID-19. If you qualify, you would receive one dose of the study vaccine and be monitored for safety and immune response.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
This study looks at how the body's immune system reacted to COVID-19 in people who had either severe or mild cases. The goal is to learn more about a specific part of the immune response (called IFN-I) to better understand the disease.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.